Drugs / CD19-directed chimeric antigen receptor (CAR-T) T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07840976 | Oct 2026 → May 2028 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07643103 | Jun 2026 → May 2028 expected | precursor B-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-directed chimeric antigen receptor (CAR-T) T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07643103 ↗ |
| Modality | Cell therapy | “Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients.” NCT07643103 ↗ |
| Route | Intravenous | “Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients.” NCT07643103 ↗ |
| Target | CD19 | “Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients.” NCT07643103 ↗ |